Page Loading...
Layout Table~~~~1435~1435~~
Cancer Antibodies: Competitive Positioning for Success~
Published by BioSeeker Group, June 2008
This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.~Published by BioSeeker Group, June 2008
This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.
In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.
Why You Should Own Your Own Copy of this Report:
260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
Pathway profiling of cancer antibody drug targets
Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
Who are working on sequels to blockbuster drugs?
Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
Sample Pages
~Cancer Antibodies%3A Competitive Positioning for Success (PDF or Hard Copy)|1200|~1435~3364~~
Cancer Vaccines: Aim and Shoot~
Published by BioSeeker Group, May 2008
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.~Published by BioSeeker Group, May 2008
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.
This report is written for you to identify your competition and understand which targeting strategies are at work within cancer vaccine drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed cancer vaccines and identified 75 drug targets belonging to 109 drugs. This report, Cancer Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer vaccine drugs.
In the report, BioSeeker reports on 66 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 109 cancer vaccine drugs designed for the treatment of 37 different cancer indications. The highest degree of distinctiveness among cancer vaccine drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer vaccine drugs. No less than 64 protein-protein interactions were recognized among and between 41 of the 75 included cancer vaccine drug targets.
Why You Should Own Your Own Copy of this Report:
180+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to related resources on the Internet
A 109 cancer vaccine drugs analysis, under development by 76 investigators, covering more than 236 developmental projects in cancer
75 unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other drug targets, pursued cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
A unique drug target combination breakdown of cancer vaccines into tumor type, compound type, and developmental stage
Unique drug-protein target and protein-protein of drug targets interactome analysis
Pathway profiling of cancer vaccine drug targets
Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
Who are working on sequels to blockbuster drugs?
Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
Table of Contents
~Cancer Vaccines%3A Aim and Shoot (PDF or Hard Copy)|1202|~1435~3367~~
The Drug Target Atlas of Apoptopic Drugs in Oncology~
Published by BioSeeker Group, February 2008
The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most. Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.~Published by BioSeeker Group, February 2008
The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most. Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.
First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology.
In the report, BioSeeker reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications. The highest degree of distinctiveness among apoptopic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.
The report by the numbers
250+ pages, with almost a hundred different tables. Includes more than 1,500 active links to related resources on the Internet
114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
90 Unique drug target combinations of apoptopic drugs
452 protein-protein interactions among apoptopic drug targets
Extensive pathway analysis of drug targets
This report serves as a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies
Table of Contents
~The Drug Target Atlas of Apoptopic Drugs in Oncology (PDF or Hard Copy)|1142|~1435~3328~~
Cancer Stem Cells - Emerging Therapeutic, Diagnostic and Market Opportunities~
Published by BioPharm Reports, January 2008
This report gives a comprehensive up-to-date review of global R&D on CSCs and strategies to target them. This includes around 30 companies or commercially based research organisations (including 20 SMEs and five major pharmaceutical companies) that are progressing drug discovery activities, including drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, current clinical trials and related areas. Also covered are current developments on the detection of CSCs and new diagnostic approaches. Commercial opportunities in drug discovery and diagnostics relating to CSCs are also presented. More than 50 academic research teams from 13 different countries are reviewed, together with leading discoveries in this field. Current patents referring to CSCs (70+ by Dec 2007) are also presented.~Published by BioPharm Reports, January 2008
Overview
Tumours and haematological cancers contain small populations of cells that are believed to play a critical role in the progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is thought that CSCs are critically involved in the development and metastatic spread of cancer. CSCs have also demonstrated resistance to a number of conventional therapies and it is thought that that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. If these findings are now confirmed in the clinic, the selective targeting of CSCs will offer a new paradigm in both cancer therapeutics and diagnostics. Currently there are more than 30 CSC R&D programmes in progress, around 50% of which are at Phase I or beyond. Patient data from the first clinical trials of drugs believed to target CSCs, are now being reported. Most CSC R&D programmes are being taken forward by SME's and > 90% of the 70 patents in this area (which more than doubled in 2007) have been filed by Universities. Substantial opportunity for collaboration is this field has recently lead to agreements between SMEs and major pharmaceutical companies. This includes a recent announcement of a collaboration between GSK and Oncomed Pharmaceuticals, Inc.
Drug Discovery and Pipeline/b>
More than ten different strategies are being actively researched to enable the selective therapeutic targeting of CSCs, which are described in this report. In December 2007, clinical data were reported on GSK's Tykerb (which is already approved in the US for breast cancer), that targets the CD44+/CD24+ population of breast cancer cells i.e. breast CSCs. ChemGenix has also recently published clinical data from a Phase II/III CML clinical trial of omacetaxine mepesuccinate, which is believed to target CSCs. Stemline Therapeutics have reported that their investigational CSC-targeting molecule SL-401, has demonstrated single agent anti-tumour activity in acute myeloid leukaemia in a multi-centre Phase I/II dose escalation study. Currently around 30 companies or commercially based research organisations are progressing R&D activities in the CSC field, 65% of which are SME's. This report identifies five "Top-25" pharmaceutical companies that are progressing developments relating to CSCs. Of the current 30 R&D programmes, around 50% are at Phase I or beyond. The availability of isolated CSCs to drug discovery companies offers opportunities to identify new druggable targets and to re-examine existing drug libraries that have not been screened against this unique subset of cells, or xenograft models developed from them.
Cancer Diagnostics
CSCs are believed to be causally linked to the development and metastatic spread of cancer. If this is confirmed in man, this will likely place CSCs at the heart of cancer diagnostics. Researchers have identified a number of surface proteins such as CD44, CD133 and many others, which may have important application as biomarkers and diagnostics. Some of these surface proteins are found on a number of different CSCs, whereas others appear to be unique to certain CSCs. A number of intracellular markers found in CSCs, may also have diagnostic utility. These developments are described in this report. CD133 mRNA levels in peripheral blood, measured using RT-PCR, have been found to predict colon cancer recurrence. There is a need for new methodologies that isolate and characterise circulating tumour cells (CTCs) in the blood, that can be applied to CSCs. CTC technologies using the EpCam marker to isolate these cells are able to predict colon cancer recurrence. The adaption of these techniques based on specific CSC phenotypes may provide sensitive new methods for identifying CSCs in the body. Innovation in advanced microfluidic, chip-based and genetic/phenotypic screening technologies are anticipated in the future. OncoMed Pharmaceuticals have announced the discovery of a gene expression profile of CSCs (breast and other cancers), that correlate with clinical outcome.
Table of Contents
~Single user license PDF|1012|Two user licenses PDF|1013|Three user licenses PDF|1014|Four user licenses PDF|1015|Five - 99 user licenses|1016|~1435~3140~~
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology~
Published by BioSeeker Group, November 2007
All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance.~Published by BioSeeker Group, November 2007
All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance.
All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance.
First in place, BioSeeker has surveyed protein kinase inhibitors in oncology and identified 110 drug targets, belonging to 210 protein kinase inhibitor drugs. This report, The Drug Target Atlas of Protein Kinase Inhibitors in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology.
In the report, BioSeeker reports on 139 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 210 PKI drugs designed for the treatment of more than 50 different cancer indications. The highest degree of distinctiveness among PKIs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified PKI drug targets. No less than 519 protein-protein interactions were recognized among 98 of the 110 included PKI drug targets.
The report by the numbers:
300+ pages, with almost a hundred different tables. Includes close to 1,000 active links to related resources on the Internet
210 Protein kinase inhibitor drugs, under development by 107 investigators, are included, covering more than 600 developmental projects in cancer
110 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other PKI drug targets, linked cancer indications, presence in the Cancer Genome Project etc.
139 Unique drug target combinations of PKI drugs
519 protein-protein interactions among PKI drug targets
20 Major signaling pathways covered
This report serves as a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
Table of Contents
~The Drug Target Atlas of Protein Kinase Inhibitors in Oncology (PDF or Hard Copy)|1135|~1435~3331~~
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas~
Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive 500+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.~Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the leukemia and lymphoma field. This extensive 500+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
The report further give an in depth analysis in two important key oncology areas; Breast- and Prostate cancer. And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
Includes references to more than 250 drugs and 600 clinical/preclinical trials
Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
Drug compound analysis by cancer indications
Gain insight into the current challenges and commercial opportunities associated with leukemia and Lymphoma therapy. Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in leukemia and Lymphoma R&D, and the results of clinical trials to date.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. In this report, BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
The leukemia and lymphoma scope of this report
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Table of Contents
~Triple Analysis%3A Decoding Big Pharma%27s R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas (PDF)|1144|~1435~3332~~
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer~
Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the breast- and prostate cancer field. This extensive 440+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.~Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the breast- and prostate cancer field. This extensive 440+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
The report further give an in depth analysis in two important key oncology areas; Breast- and Prostate cancer . And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
Includes references to more than 250 drugs and 600 clinical/preclinical trials
Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
Drug compound analysis by cancer indications
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been initiated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field
Table of Contents
~Triple Analysis%3A Decoding Big Pharma%27s R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer (PDF)|1145|~1435~3334~~
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma~
Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the lung cancer and melanoma field. This extensive 510+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.~Published by BioSeeker Group, September 2007
This is the report for professionals interested to grasp big pharma’s R&D strategy in oncology and at the same time have an extensive R&D overview of the lung cancer and melanoma field. This extensive 510+ pages report compiles and analyzes Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
The report further give an in depth analysis in two important key oncology areas; Lung- and Melanoma cancer. And provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
Includes references to more than 250 drugs and 600 clinical/preclinical trials
Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
Drug compound analysis by cancer indications
The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine)
Table of Contents
~Triple Analysis%3A Decoding Big Pharma%27s R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma (PDF)|1146|~1435~3336~~
Decoding Big Pharmas R&D Strategy in Oncology~
Published by BioSeeker Group, September 2007
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.~Published by BioSeeker Group, September 2007
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.
BioSeeker has in this very insightful publication focused on Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five included big pharma companies. The collective force of the above research and analysis ’decodes’ these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.
Decoding Big Pharma’s R&D Strategy in Oncology in numbers:
Includes references to more than 250 drugs and 600 clinical/preclinical trials
Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, targets affecting signaling pathways etc
Drug compound analysis by cancer indications
Table of Contents
~Decoding Big Pharmas R&D Strategy in Oncology (PDF or Hard Copy)|1136|~1435~3316~~
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC~
Published by BioSeeker Group, July 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC, which are all subjects to an extensive number of innovative drug candidates. This extensive 450+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.~Published by BioSeeker Group, July 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC, which are all subjects to an extensive number of innovative drug candidates. This extensive 450+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies
The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been or are comparing different combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).
Table of Contents
~Triple Analysis%3A Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC (PDF)|1141|~1435~3326~~
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas~
Published by BioSeeker Group, June 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.~Published by BioSeeker Group, June 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug target, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies
Gain insight into the current challenges and commercial opportunities associated with leukemia and Lymphoma therapy. Explore the strengths and weaknesses associated with compounds in clinical development and the scientific rationale for most novel therapeutics in leukemia and Lymphoma R&D.
Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. In this report, BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
Table of Contents
~Triple Analysis%3A Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas (PDF)|1140|~1435~3324~~
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer~
Published by BioSeeker Group, June 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.~Published by BioSeeker Group, June 2007
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
Thorough examination of status and impact of several novel drugs in development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field
Key reasons to read this report
This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy
Table of Contents
~Triple Analysis%3A Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer (PDF)|1139|~1435~3322~~
Antibody Drug Target Atlas in Oncology~
Published by BioSeeker Group, June 2007
The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in development for the treatment of cancer. What and where they are targeting has to date only been a fragmented knowledge. First in place, BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place.~Published by BioSeeker Group, June 2007
The elaborate advances towards the blueprinting of the altered molecular networks that lie behind cancer development have paved the way for targeted therapy in cancer. There are currently more than 400 antibody based drugs in development for the treatment of cancer. What and where they are targeting has to date only been a fragmented knowledge. First in place, BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
34 Different molecular functions of target
13 Major signaling pathways
Cancer stem cells
Conjugated antibodies
Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
31 Targeted cancer indications
Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
Antibody therapeutic companies
Single target analysis of the 132 antibody targets is performed, including targeted cancer indications, antibody drugs involved and their developmental stages. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.
This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.~Antibody Drug Target Atlas in Oncology (PDF)|1056|Antibody Drug Target Atlas in Oncology (Hard Copy)|1057|~1435~3243~~
Brain Cancer Drug Pipeline Update 2007~
Published by BioSeeker Group, May 2007
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available.~Published by BioSeeker Group, May 2007
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available.
Datamonitor predicts that there will be around 26,000 new cases of glioblastoma multiforme diagnosed in the seven major markets (US, Japan, France, Germany, Italy, Spain and UK) in 2007. In the US alone, around 14,000 people will die from brain cancer in 2007.
There are today more than 120 therapeutics targeting brain cancer, from early preclinical to marketed drugs. Brain Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 77 different targets. These targets are further categorized on the CD-ROM by 29 classifications of molecular function and their possible belonging to 17 different signaling pathways in the cell. Read more below on how the Brain Cancer Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
Find competitors, collaborations partners, M&A candidates etc.
Jump start competitive drug intelligence operations
Excellent starting point for world wide benchmarking
Compare portfolio and therapy focus with your peers
Speed up pro-active in-/out licensing strategy work
Fast and easy way of tracking drugs using search engines; just one click and you may search the World Wide Web and PubMed for any drug.
Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Investigators Includes more than 100 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.
Note
: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.
Drug name & Synonyms Lists commercial, generic and code names for drugs. In all more than 240 names Developmental stage This Drug Pipeline Update contains more than 120 drugs in active development for the treatment of brain cancer:
10 marketed drugs
9 drugs in Phase III
49 drugs in Phase II
23 drugs in Phase I
30 drugs in Preclinical
Note
: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included 120+ drugs are also in development for over 100 other indications.
Note
: You are able to sort and find drugs according to type of indication from drop-down menu in the application.
Targets Identified drugs are linked to 77 different targets, divided into 29classifications of molecular function:
Auxiliary transport protein activity
Catalytic activity
Cell adhesion molecule activity
Cysteine-type peptidase activity
Cytokine activity
DNA repair protein
DNA topoisomerase activity
DNA-directed DNA polymerase activity
Extracellular ligand-gated ion channel activity
G-protein coupled receptor activity
Growth factor activity
Kinase activity
Ligand-dependent nuclear receptor activity
Lipid kinase activity
Lipid phosphatase activity
Peptidase activity
Protein serine/threonine kinase activity
Protein-tyrosine kinase activity
Receptor activity
Receptor signaling protein serine/threonine kinase activity
Receptor signaling protein tyrosine phosphatase activity
Structural constituent of cytoskeleton
T cell receptor activity
Transcription factor activity
Transcription regulator activity
Transferase activity
Translation regulator activity
Transmembrane receptor activity
Transmembrane receptor protein tyrosine kinase activity
Identified targets are categorized into 11 different primary and alternate localizations:
Clathrin-coated vesicle
Cytoplasm
Cytosol
Endoplasmic reticulum
Endosome
Extracellular
Mitochondrion
Nucleolus
Nucleus
Plasma membrane
Secreted
Note
: You are able to sort and find drugs according to target name, molecular function of target, and target localization from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to protein expression profiles of 35 drug targets in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Signaling Pathways Identified targets have been cross referenced against 20 signaling pathways, and no less than 17 are currently being pursued in brain cancer drug development:
Alpha6 Beta4 Integrin Signaling Pathway
Androgen Receptor Signaling Pathway
B Cell Receptor Signaling Pathway
EGFR1 Signaling Pathway
IL-1 Signaling Pathway
IL-2 Signaling Pathway
IL-3 Signaling Pathway
IL-4 Signaling Pathway
IL-5 Signaling Pathway
IL-6 Signaling Pathway
IL-9 Signaling Pathway
Kit Receptor Signaling Pathway
Notch Signaling Pathway
T Cell Receptor Signaling Pathway
TGF-beta Receptor Signaling Pathway
TNF-alpha Signaling Pathway
Wnt Signaling Pathway
Note
: You are able to sort and find drugs according to targeted signaling pathway from drop-down menu in the application.
Mechanism In total there are at least 90 different drug mechanism of action represented in this Drug Pipeline Update.
Note
: You are able to sort and find drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note
: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Drug Profile Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms (if any)
Principal Investigator & Partners
Presentation of principal investigator and partners (if any)
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol - Official Gene Name [Species/Homo Sapiens] - Molecular Function
Target Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Signaling Pathways
Described target(s) is/are matched for the involvement in 20 major signaling pathways.
Mechanism
Drug mechanism of action
Developmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma - Phase II Clinical Trial - Active
Cancer, prostate - Phase III Clinical Trial - Ceased
Drug Description
Short introduction to drug
Compound Data
Compound type, Chemical name, CAS Number and molecular weight
Patent Data
Available patent information related to the drug is presented here.
Business & Markets
Collaborations and deals
Approvals and submissions
Analyst comments
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Preclinical Data
Available preclinical development data, developmental history and scientific data.
Licensing Information
Availability for licensing
Application Features Use 13 different parameters, available in drop-down menus, to find and sort among drugs
Drug status
Clinical Trial Status
Principle Investigator
Partners
Indication
Developmental Stage
Compound Type
Mechanism
Target
Molecular Function of Target
Target Localization
Targeted Signaling Pathways
Free text search of entire drug profile contents
Direct linkage from inside the application to related internet resources
Drug data is linked to search engines like Google and PubMed
Target data is linked directly to Human Protein Atlas
Direct links to company web pages of principal investigators
Export and sharing of information
Found information is easily shared with others over e-mail, file export (xls) or in print
System Requirements:
AMD-Athlon/Pentium II PC
Windows 98/NT4/2000/ME/XP
8x-speed CD Rom drive
SVGA 16 bit display. (32 bit recommended)
32 MB of available RAM (128 MB recommended)
Internet access (for related internet resources)
~Brain Cancer Drug Pipeline Update 2007 (CD-ROM)|1137|~1435~3318~~
Global Cancer Focus Company Directory~
Published by BioSeeker Group, April 2007
Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, including almost 900 hundred companies in 39 different countries. Global Cancer Focus Company Directory breaks down all companies into their involvement in 81 different cancer indications, also including supportive care and diagnosis.
Global Cancer Focus Company Directory is a CD-ROM product with a 98 pages supplementary PDF included. The CD-ROM product is based on BioSeeker’s proprietary CD-ROM technology which includes smart database structure, find and sort options, internet and e-mail interactivity. Found information on the CD-ROM may easily be shared with others via file export (txt and xls), e-mail or print.~Published by BioSeeker Group, April 2007
Executive Summary
Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, including almost 900 hundred companies in 39 different countries. Global Cancer Focus Company Directory breaks down all companies into their involvement in 81 different cancer indications, also including supportive care and diagnosis.
Global Cancer Focus Company Directory is a CD-ROM product with a 98 pages supplementary PDF included. The CD-ROM product is based on BioSeeker’s proprietary CD-ROM technology which includes smart database structure, find and sort options, internet and e-mail interactivity. Found information on the CD-ROM may easily be shared with others via file export (txt and xls), e-mail or print.
Each company profile reports on:
Cancer Focus (Includes 81 different cancer indications)
Year Founded
Ownership (Private/Public)
Contact details (Address, Phone, Fax, Web and E-mail)
A brief company description
All companies are provided with links, which connect you directly to the company webpage for further research. Companies can be further researched on from inside the application by linking search queries directly to search engines like Google and PubMed.
How May This Product Be of Use?
Comprehensive source of oncology companies
Find new and emerging companies in oncology
Find out your potential competitors, partners, M&A candidates etc. on a cancer indication specific level
Jump start competitive intelligence operations
Excellent starting point for world-wide benchmarking
Speed up pro-active in-/out-licensing strategy work
Track companies over time using search engines
Show investors/board/management that you are right on top of industry development
System Requirements
AMD-Athlon/Pentium II PC
Windows 98/NT4/2000/ME/XP/Vista
8x-speed CD Rom drive
SVGA 16 bit display. (32 bit recommended)
32 MB of available RAM (128 MB recommended)
Internet access (to test web-enabled presentations)
Table of Contents
~Global Cancer Focus Company Directory (PDF)|1034|Global Cancer Focus Company Directory (CD-ROM)|1035|~1435~3149~~
Targeted Therapeutics in Non-Small Cell Lung Cancer~
Published by BioSeeker Group, April 2007
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data.~Published by BioSeeker Group, April 2007
Introduction
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for non-small cell lung cancer (NSCLC): cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. New data on platinum-based chemotherapy has been presented. Both Avastin and Efaproxyn have generated additional data.
In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 22 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for NSCLC and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).
Example of drugs included in this study
Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474,
Example of companies included in this study
Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik
Scope of this report
Thorough examination of status and impact of many novel drugs in developmentDiscussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Case studies on major lung cancer drugs on market and in development.
Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date. Gain insight into the current challenges and commercial opportunities associated with lung cancer
Table of Contents
~Targeted Therapeutics in Non-Small Cell Lung Cancer (PDF)|1032|Targeted Therapeutics in Non-Small Cell Lung Cancer (Hard Copy)|1033|~1435~3145~~
Global Pipeline Review & Analysis of Hematological Malignancies~
Published by BioSeeker Group, March 2007
The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.~
Published by BioSeeker Group
Introduction
The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
About this report
n this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:
Investigator - Includes 212 investigators and partners
Drug - Includes 237 "active" drugs
Sub-indication - Includes 11 sub-indications
Developmental stage - Includes 8 developmental stages
Compound type - Includes 21 different compounds types
Targeted therapy strategy - Includes 5 different targeted therapy strategies
Target - Includes 97 different protein targets
Signaling pathway - Includes 18 different signaling pathways
All of above "factors" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each "factor" included in this cutting edge analysis.
Investigator
This report includes 212 investigators and partners from all over the world.
Drug
There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description.
Sub-indication
The hematological cancer drug pipeline is broken down into 11 sub-indications:
Cancer, leukemia, acute lymphocytic
Cancer, leukemia, acute myelogenous
Cancer, leukemia, chronic lymphocytic
Cancer, leukemia, chronic myelogenous
Cancer, leukemia, general
Cancer, leukemia, hairy cell
Cancer, lymphoma, B-cell
Cancer, lymphoma, general
Cancer, lymphoma, Hodgkin`s
Cancer, lymphoma, non-Hodgkin`s
Cancer, lymphoma, T-cell
Only the highest developmental stage per drug and indication is accounted for.
Developmental Stage
Each sub-indication of a drug is described with its developmental stage:
Preclinical
Clinical Trial
Phase I Clinical Trial
Phase II Clinical Trial
Phase III Clinical Trial
Pre-registration
Registered
Marketed
Compound Type
BioSeeker has described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:
Biological
Biological, bacterial cells
Biological, cellular, autologous
Biological, cellular, heterologous
Biological, nucleic acid
Biological, nucleic acid, non-viral vector
Biological, nucleic acid, viral vector
Biological, peptide
Biological, peptide, recombinant
Biological, protein
Biological, protein, antibody
Biological, protein, recombinant
Chemical, semisynthetic
Chemical, synthetic
Chemical, synthetic, isomeric
Chemical, synthetic, nucleic acid
Chemical, synthetic, peptide
Natural product
Natural product, animal
Natural product, bacterial
Natural product, plant
When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight.
Targeted Therapy Strategy
This report categorizes available drugs into 5 major targeted therapy strategies:
1.Angiogenesis
2. Antibody
3. Apoptosis
4. Protein Kinase Inhibitors
5. Vaccines
Target
This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:
Primary Localization of Target:
Cell surface
Centrosome
Cytoplasm
Cytosol
Endoplasmic reticulum
Extracellular
Integral to membrane
Lysosome
Mitochondrial membrane
Mitochondrion
Nucleus
Plasma membrane
Secretory granule
Molecular Class of Target:
Adapter molecule
Adhesion molecule
Cell cycle control protein
Cell surface receptor
Chaperone
Cysteine protease
Cytokine
Cytokine receptor
Cytoskeletal protein
DNA methyltransferase
DNA polymerase
DNA repair protein
Enzyme: Deaminase
Enzyme: Decarboxylase
Enzyme: Hydrolase
Enzyme: Ligase
Enzyme: Oxidoreductase
Enzyme: Phosphorylase
Enzyme: Topoisomerase
Enzyme: Transferase
G protein coupled receptor
Growth factor
Integral membrane protein
Ligand
Lipid phosphatase
Membrane bound ligand
MHC complex protein
Nuclear receptor
Receptor tyrosine kinase
Serine protease
Serine/threonine kinase
T cell antigen receptor
Transcription factor
Transcription regulatory protein
Translation regulatory protein
Transport/cargo protein
Tyrosine kinase
Unclassified
Molecular Function of Target:
Carboxy-lyase activity
Cell adhesion molecule activity
Chaperone activity
Cysteine-type peptidase activity
Cytokine activity
Deaminase activity
DNA repair protein
DNA topoisomerase activity
DNA-directed DNA polymerase activity
DNA-methyltransferase activity
G-protein coupled receptor activity
Growth factor activity
Hydrolase activity
Kinase activity
Ligand-dependent nuclear receptor activity
Ligase activity
Lipid phosphatase activity
MHC class I receptor activity
Molecular function unknown
Oxidoreductase activity
Phosphorylase activity
Protein binding
Protein serine/threonine kinase activity
Protein-tyrosine kinase activity
Receptor activity
Receptor binding
Receptor signaling complex scaffold activity
Serine-type peptidase activity
Structural constituent of cytoskeleton
T cell receptor activity
Transcription factor activity
Transcription regulator activity
Transferase activity
Translation regulator activity
Transmembrane receptor activity
Transmembrane receptor protein tyrosine kinase activity
Transporter activity
Unclassified
Biological Process of Target:
Anti-apoptosis
Apoptosis
Cell communication
Cell communication ; Cell surface receptor linked signal transduction
Cell communication ; Signal transduction
Cell communication ; Signal transduction ; Transport
Cell growth and/or maintenance
Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
Immune response
Metabolism
Metabolism ; Energy pathways
Protein metabolism
Protein modification
Regulation of cell cycle
Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
Signal transduction
Transport
Signaling Pathway
The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:
Alpha6 Beta4 Integrin Signaling Pathway
Androgen Receptor Signaling Pathway
B Cell Receptor Signaling Pathway
EGFR1 Signaling Pathway
ID Signaling Pathway
IL-1 Singaling Pathway
IL-2 Signaling Pathway
IL-3 Signaling Pathway
IL-4 Signaling Pathway
IL-5 Signaling Pathway
IL-6 Signaling Pathway
IL-7 Signaling Pathway
Kit Receptor Signaling Pathway
Notch Signaling Pathway
T Cell Receptor Signaling Pathway
TGF-beta Receptor Signaling Pathway
TNF-alpha Signaling Pathway
Wnt Signaling Pathway
Table of Contents
~Global Pipeline Review & Analysis of Hematological Malignancies (PDF)|997|Global Pipeline Review & Analysis of Hematological Malignancies (Hard Copy)|998|~1435~3127~~
Prostate and Breast Cancer- New Treatments & Developmental Progress~
Published by BioSeeker Group, March 2007
The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. Newly approved drugs are showing increased sale figures, and several of them are reaching for broader indications. So, the trend of continuously increasing revenues is expected for drugs presenting reliable clinical data to support their successful progress.~Published by BioSeeker Group, March 2007
Introduction
The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. Newly approved drugs are showing increased sale figures, and several of them are reaching for broader indications. So, the trend of continuously increasing revenues is expected for drugs presenting reliable clinical data to support their successful progress.
Research and analysis highlights
In the report "Prostate & Breast Cancer - New Treatments & Developmental Progress" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate and breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified approximately 200 drug candidates in clinical stage of development and more than 125 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in these markets and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report
Thorough examination of status and impact of several novel drugs in developmentDiscussion of the challenges in current and future treatment strategiesAnticancer pipeline of most companies in the fieldKey reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development.Scientific rationale for most novel therapeutics in breast and prostate cancer R&D, and the results of clinical trials to dateGain insight into the current challenges and commercial opportunities associated with breast and prostate cancer therapy
Two hundred high quality references
Some of the drugs included in this analysis:
4HPR, Anastrozole, Arsenic trioxide, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, DCVax-prostate, Doxorubicin, Epothilone D, Erlotinib, Exemestane, Exisulind, Fulvestrant, Gefitinib, Goserelin, GVAX, Imatinib, ixabepilone, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Oblimersen sodium, Patupilone, Pemetrexed, PTK/ZK, R-flurbiprofen, Toremifene Temsirolimus, Theratope, Tipifarnib, Trastuzumab, Satraplatin, SDX-105, sipuleucel-T, Sorafenib tosylate, Vapreotide
Some of the companies included in this analysis:
Antigenics, AstraZeneca, Bayer, Baxter International, Biomira, Bristol Myers-Squibb, Cell Genesys, Cephalon, Debiopharm, Dendreon, Eli Lilly, Encore Pharmaceuticals, Genentech, GlaxoSmithKline, Genta, GTx, Isis Pharmaceuticals, Johnson and Johnson, Kosan Biosciences, Lorus Therapeutics, Merck, Millennium Pharmaceutical, Northwest Biotherapeutics, Novartis, Orion Pharma, OSI Pharmaceuticals, NeoRx, Novartis Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough, Wyeth, YM BioSciences
Table of Contents
~Prostate and Breast Cancer- New Treatments & Developmental Progress (PDF)|999|Prostate and Breast Cancer- New Treatments & Developmental Progress (Hard Copy)|1000|~1435~3129~~
Breast Cancer - Therapeutic And Competitive Insights~
Published by BioSeeker Group, February 2007
Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100 000 women from tamoxifen to Arimidex will cost nearly 100 million.~Published by BioSeeker Group, February 2007
Introduction
Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100 000 women from tamoxifen to Arimidex will cost nearly 100 million.
Research and analysis highlights
In the report "Breast Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies. Hormone modifying therapies together with different chemotherapeutic schedules have been of highest intrest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
Scope of this report
Thorough examination of status and impact of several novel drugs in developmentDiscussion of the challenges in current and future treatment strategiesAnticancer pipeline of most companies in the field
Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast cancer R&D, and the results of clinical trials to dateGain insight into the current challenges and commercial opportunities associated with breast cancer therapy
One hundred high quality references
Some of the drugs included in this analysis:
4HPR, Anastrozole, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, Erlotinib, Exemestane, Fulvestrant, Gefitinib, Goserelin, Imatinib, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Patupilone, Pemetrexed, Temsirolimus, Theratope, Tipifarnib, Trastuzumab, SDX-105.
Some of the companies included in this analysis:
AstraZeneca, Baxter International, Biomira, Bristol Myers-Squibb, Eli Lilly, Genentech, GlaxoSmithKline, GTx, Isis Pharmaceuticals, Johnson and Johnson, Lorus Therapeutics, Merck, Millennium Pharmaceutical, NeoRx, Novartis Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough, Wyeth, YM BioSciences
Table of Contents
~ Breast Cancer%3A The Latest R&D Trends%3A PDF Version|334| Breast Cancer%3A The Latest R&D Trends%3A Hard Copy|723|~1435~1807~~
Top 7 Cancer Indications - Therapeutic & Competitive Insights~
Published by BioSeeker Group, January 2007
In the report BioSeeker does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.~Published by BioSeeker Group, January 2007
With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, and Prostate cancer.
No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications.
In the report BioSeeker does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report:
Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls
Breast Cancer
Colon/colorectal cancer
Leukemia
Lung cancer
Lymphoma
Melanoma
Prostate Cancer
Includes more than 250 drug developing companies
Includes more than 360 candidate drugs
The report includes more than 160 Tables, 200 Boxes and 600 high quality references
Key reasons to read this report:
Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indicationsAssess opportunities and risks for the continued development of drugs in seven major cancer indicationsAdopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
Pages: 750
table of Contents
~Top 7 Cancer Indications - Therapeutic & Competitive Insights (PDF)|1084|~1435~3275~~
Prostate Cancer - A Therapeutic & Competitive Insight~
Published by BioSeeker Group, January 2007
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006.~
Untitled Document
Published by BioSeeker Group, January 2007
Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate ca